CD8A and neoplasm: Further analysis of CD8+ and CD4+ T-cell populations revealed that mice treated with both anti-CAIX CAR-T cells and LB-100 demonstrated significantly higher quantities of CD8+ and CD4+ T cells at the tumor site (Figure 4C).